First Experience With Extravascular Implantable Cardioverter‐Defibrillator Under Deep Sedation
Open Access
- 20 June 2026
- journal article
- Published by Wiley in Pacing and Clinical Electrophysiology
Abstract
Background: The Extravascular Implantable Cardioverter‐Defibrillator (EV‐ICD) utilizes a substernal lead to provide defibrillation and anti‐tachycardia pacing (ATP) while avoiding transvenous complications. General anesthesia (GA) was applied for implantation procedures in the EV‐ICD pivotal trial and is currently recommended by the manufacturer. However, GA carries specific risks and consumes significant resources. This study evaluates the feasibility, safety, and procedural efficiency of EV‐ICD implantation performed under cardiologist‐administered deep sedation with noninvasive ventilation (DS‐NIV) compared to standard GA. Methods: We retrospectively analyzed 24 consecutive patients undergoing EV‐ICD implantation in our center. Patients received either GA ( n = 14) or DS‐NIV ( n = 10) using a propofol‐ketamine protocol delivered by cardiologists. Analyses focused on peri‐procedural feasibility and safety, procedural workflow and anesthesia characteristics, and early device electrical performance. Results: No anesthesia‐related complications occurred in either group. The DS‐NIV group demonstrated significantly shorter wheels‐to‐incision times (median: 45 vs. 70 min, p = 0.022), whereas the procedural duration did not differ significantly from the GA group. Patients receiving DS‐NIV required fewer vasopressors (60% vs. 100%, p = 0.024) despite higher propofol infusion rates (800 vs. 350 mg/h, P <0.001). Defibrillation testing success and electrical parameters were comparable. In a median follow‐up of 182 days two patients received appropriate EV‐ICD therapies and no inappropriate ATP or shocks were delivered. Conclusion: EV‐ICD implantation under cardiologist‐administered DS‐NIV appears to be feasible and safe, offering improved workflow efficiency compared to GA. These findings support deep sedation as a practical alternative in experienced centers, potentially expanding access to EV‐ICD therapy.Keywords
This publication has 26 references indexed in Scilit:
- Extravascular implantable cardioverter-defibrillator therapy in patients with genetic heart disease: An early single-center experienceHeart Rhythm O2, 2025
- Periprocedural outcomes from the postmarket study of the extravascular implantable cardioverter-defibrillator: Preliminary Enlighten study results and meta-analysisHeart Rhythm, 2025
- Preventive Catheter Ablation for Ventricular Arrhythmias in Patients with End-Stage Heart Failure Referred for Heart Transplantation Evaluation: Rationale for and Design of the CASTLE-VT TrialEuropean Journal of Heart Failure, 2024
- Effects of Atrial Fibrillation Ablation on Arrhythmia Burden and Ventricular Function in End-Stage Heart Failure: Lessons from CASTLE-HTxEuropean Journal of Heart Failure, 2024
- Bilevel positive airway pressure ventilation in patients susceptible to hypoxemia during procedural sedation for colonoscopy: a prospective randomized controlled studyGastrointestinal Endoscopy, 2023
- A randomized controlled trial of the intraoperative use of noninvasive ventilation versus supplemental oxygen by face mask for procedural sedation in an electrophysiology laboratoryCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 2023
- Tumescent local anesthesia versus general anesthesia for subcutaneous implantable cardioverter-defibrillator implantationHeart Rhythm, 2021
- Ventricular tachycardia burden reduction after substrate ablation: Predictors of recurrenceHeart Rhythm, 2021
- Predictive Factors and Safety of Noninvasive Mechanical Ventilation in Combination With Propofol Deep Sedation in Left Atrial Ablation ProceduresThe American Journal of Cardiology, 2019
- Feasibility of extravascular pacing with a novel substernal electrode configuration: The Substernal Pacing Acute Clinical Evaluation studyHeart Rhythm, 2018